Carregant...
The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
AT13387 is an orally bioavailable clinical candidate developed to inhibit theheat shock protein 90 (Hsp90). This article describes a modified synthetic route for the multi-gram production of AT13387 in 46% overall yield. The modified synthetic route is short, avoids stringent reaction conditions and...
Guardat en:
| Publicat a: | Synth Commun |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7577423/ https://ncbi.nlm.nih.gov/pubmed/33093687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/00397911.2019.1602654 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|